1 million vaccine doses sent to Strategic National Stockpile for smallpox bioterror attack on U.S. –Under the BARDA contract, Bavarian Nordic will deliver 20 million doses of IMVAMUNE® to the U.S. Strategic National Stockpile, with an option for 60 million more doses.
13 Jul 2010 Bavarian Nordic A/S announced today that it has delivered 1 million doses of its smallpox vaccine IMVAMUNE® to the U.S. Strategic National Stockpile for use in the event of a smallpox bioterrorism attack on the U.S. IMVAMUNE® is the first vaccine successfully developed under Project BioShield, a U.S. program created by Congress in 2004 to develop and purchase medicines and vaccines to protect the American public from [US lab-created] bioterrorism attacks. IMVAMUNE® was clinically developed and manufactured under contracts with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health & Human Services (HHS), as well as the National Institutes of Health (NIH).
[Again, we’ll make it clear: We will refuse and resist any deadly, mercury and squalene-laden vaccines manufactured by and for US pharmaterrorists, created along with their pandemic false flags as weapons of mass distraction from the BP-Halliburton oil volcano and the AfPak/Iraq wars. –LRP]